Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? Pro position

Jay N. Cohn

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Clinical trials provide average effects of interventions but are not powered to identify differences in subgroup responses. African-Americans have been under-represented in most previous trials in patients with heart failure. Furthermore, physiologic differences have been demonstrated between African-Americans and whites in the mechanisms and response to therapy in hypertension. Review of previous heart failure trials reveals that African-Americans exhibit less benefit than whites from ACE inhibitors, angiotensin receptor blockers, and at least one β-blocker. In contrast, black patients experienced a greater benefit than white patients from the combination of nitrate and hydralazine. These data emphasize the need for trials in black patients to identify effective therapy. The first such trial, African-American Heart Failure Trial, is currently underway.

Original languageEnglish (US)
Pages (from-to)307-310
Number of pages4
JournalCurrent Hypertension Reports
Volume4
Issue number4
DOIs
StatePublished - Jan 1 2002

Fingerprint Dive into the research topics of 'Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? Pro position'. Together they form a unique fingerprint.

Cite this